Projects per year
A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
Moore, M., Singhal, N., Chin, V. T., Karikios, D., Houghton, B., Chan, M. M. K. & Hawkins, C.
29/10/19 → 31/12/23
A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma.
Moore, M. & Hawkins, C.
30/08/19 → 31/12/23
Research Output per year
Research output: Contribution to journal › Article › Other › peer-review